Clinical Trials Browser

OTHER × pembrolizumab × Other solid neoplasm × Clear all

NCT02959463 2026-03-06

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Phase 1 Active not recruiting

24 enrolled 11 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04166734 2026-02-04

MESO-PRIME

Phase 1 Terminated

5 enrolled 13 charts

Other solid neoplasmThoracic

Mesothelioma

NCT02856425 2026-01-20

PEMBIB

Phase 1 Completed

Other solid neoplasm

Patients With Any Advanced Solid Tumors

NCT06006923 2026-01-20

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Phase 2 Terminated

GastrointestinalOther solid neoplasm

MSI-H Colorectal Cancer

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

Other solid neoplasm

Solid Tumor Malignancies

NCT03760575 2025-12-04

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Phase 1 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 1 Active not recruiting

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT06576037 2025-10-15

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Phase 1 Recruiting

Other solid neoplasm

Solid Tumor

NCT02414269 2025-10-08

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1/2 Active not recruiting

BreastOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis

NCT05978102 2025-07-23

A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06719362 2025-07-10

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT02399371 2025-06-11

Pembrolizumab in Treating Patients With Malignant Mesothelioma

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02608385 2025-06-08

Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumor

NCT06318286 2025-05-25

PENINSULA

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04171219 2025-05-16

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

Phase 2 Terminated

31 enrolled 15 charts

Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT04287829 2024-11-05

PEMMELA

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03546426 2024-10-01

MESOVAX

Phase 1 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Disease Progression

NCT02707666 2024-07-31

A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

Phase 1 Terminated

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT03654833 2023-03-14

MiST

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05035381 2021-09-05

PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer

Phase 2 Unknown

GastrointestinalOther solid neoplasm

MSI-H Advanced Colorectal Cancer

NCT02987166 2020-12-16

UVA-AM-001

Phase 1 Completed

Other solid neoplasm

Solid Tumor

NCT04201145 2020-11-17

Pembrolizumab + Defactinib In Pleural Mesothelioma

Phase 1 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02843204 2020-05-28

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Phase 1/2 Completed

Other solid neoplasm

Malignant Solid Tumour

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Phase 1/2 Unknown

GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms